戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ory process that can lead to cardiomyopathy (Chagas disease).
2 nts for a growing proportion of new cases of Chagas disease.
3 omen of childbearing age prevents congenital Chagas disease.
4 cellular parasite and the etiologic agent of Chagas disease.
5 and CD1d by CD14(+) cells from patients with Chagas disease.
6 m of human African trypanosomiasis (HAT) and Chagas disease.
7  worse ventricular function in patients with Chagas disease.
8       Benznidazole is the drug of choice for Chagas disease.
9  Trypanosoma cruzi, the etiological agent of Chagas disease.
10 kg/day for 60 days in 30 adults with chronic Chagas disease.
11 in these areas that aid in the management of Chagas disease.
12  Trypanosoma cruzi, the parasite that causes Chagas disease.
13 yme, can cure the acute and chronic forms of Chagas disease.
14 nfants (4.9%) were diagnosed with congenital Chagas disease.
15 of Trypanosoma cruzi, the etiologic agent of Chagas disease.
16 ites in the hearts of those who succumbed to Chagas disease.
17 liant squaramides as candidates for treating Chagas disease.
18 te Trypanosoma cruzi, the causative agent of Chagas disease.
19 o capture the TcVac2-induced protection from Chagas disease.
20  Trypanosoma cruzi is the etiologic agent of Chagas disease.
21  the clinical and epidemiological aspects of Chagas disease.
22 factor to prevent myocardial damage in human Chagas disease.
23 ty on parasitemia in a murine model of acute Chagas disease.
24  Trypanosoma cruzi is the causative agent of Chagas disease.
25 vidence of its effectiveness against chronic Chagas disease.
26 nsible for human African trypanosomiasis and Chagas disease.
27 an Trypanosoma cruzi, the causative agent of Chagas disease.
28 ore attention and efforts towards control of Chagas disease.
29 an Trypanosoma cruzi, the causative agent of Chagas disease.
30 st Trypanosoma cruzi, the causative agent of Chagas disease.
31 rocycles can lead to useful cidal agents for Chagas disease.
32 an adjuvant therapy for treatment of chronic Chagas disease.
33 cellular parasite and the causative agent of Chagas disease.
34 hanisms and identify therapeutic targets for Chagas disease.
35 e an important factor in the pathogenesis of Chagas disease.
36 merica and often leads to the development of Chagas disease.
37  leads for the development of drugs to treat Chagas disease.
38  pathomechanism of sustained inflammation in Chagas disease.
39  drugs to develop an efficient treatment for Chagas disease.
40 ction and oxidative stress may contribute to Chagas disease.
41 r efficacy studies in a mouse model of acute Chagas disease.
42 aetiological agent of the neglected tropical Chagas disease.
43 luding Trypanosoma cruzi, the agent of human Chagas disease.
44 osoma cruzi, is an important drug target for Chagas disease.
45  allow an efficacy study in a mouse model of Chagas disease.
46 e Trypanosoma cruzi, the aetiologic agent of Chagas disease.
47 d women, 1,271 (21.8%) screened positive for Chagas disease.
48 ruzi replication, a parasite responsible for Chagas disease.
49 bolomic data to develop novel treatments for Chagas disease.
50 resents a new candidate for the treatment of Chagas disease.
51 tion have been used to study heart damage in Chagas disease.
52 ac pathology in a BALB/c mouse model of live Chagas disease.
53 logy in both the acute and chronic phases of Chagas disease.
54 4.4%) patients, 2 of them in early stages of Chagas disease.
55 onsible for prominent systemic congestion in Chagas disease.
56 e whole-blood transcriptome of patients with Chagas disease.
57 f digestive pathologies of clinical forms of Chagas disease.
58 in Trypanosoma cruzi, the causative agent of Chagas' disease.
59 ypanosomal activity in patients with chronic Chagas' disease.
60 nd more effective drugs for the treatment of Chagas' disease.
61 he clinical onset and progression of chronic Chagas' disease.
62 istry efforts to develop drug candidates for Chagas' disease.
63 dioprotective role during the acute stage of Chagas' disease.
64 an Trypanosoma cruzi, the causative agent of Chagas' disease.
65 utaneous infection in a mouse model of acute Chagas' disease.
66 e events in nervous tissues of patients with Chagas' disease.
67  Trypanosoma cruzi is the etiologic agent of Chagas' disease.
68 ssion of parasite burden in a mouse model of Chagas' disease.
69 were uninfected control patients and 120 had Chagas disease (1 group had asymptomatic disease, and 2
70 atients with indeterminate/digestive form of Chagas disease (35.7%) compared with those with Chagas c
71  cruzi parasites are the causative agents of Chagas disease, a leading infectious form of heart failu
72                                          For Chagas disease, a more extensive validation of the test
73 rypanosoma cruzi is the etiological agent of Chagas disease, a neglected and emerging tropical diseas
74                                              Chagas disease, a neglected tropical disease discovered
75 zi is a protozoan parasite that causes human Chagas' disease, a leading source of congestive heart fa
76 ma cruzi, the protozoan parasite that causes Chagas' disease, a potential life-threatening illness en
77  Trypanosoma cruzi (the etiological agent of Chagas disease) adapting via trade-off among three diffe
78      The most threatening trypanosomiasis is Chagas disease, affecting up to 12 million people in the
79                                              Chagas disease affects an estimated 300,000 individuals
80  suicide, liver cancer, diabetes, cirrhosis, Chagas disease, African trypanosomiasis, melanoma, and o
81 t patients diagnosed in the chronic phase of Chagas disease already exhibit heart involvement, and th
82                     Trypanosoma cruzi causes Chagas disease (American trypanosomiasis), which threate
83 gnoses included schistosomiasis (Africa) and Chagas disease (Americas).
84                There is a high prevalence of Chagas disease among Latin American immigrants diagnosed
85 ct physiology, but also is a major vector of Chagas disease, an illness that affects approximately se
86    Trypanosoma cruzi, the parasitic agent of Chagas disease and a public health concern throughout La
87 runcated into fragments that are specific to Chagas disease and have the potential to be used as diag
88 BIA platform for in situ diagnosis of human (Chagas disease and human brucellosis) and animal (bovine
89 gress to viable candidate compounds to treat Chagas disease and human sleeping sickness.
90 nt and severe manifestation of human chronic Chagas disease and is characterized by heart failure, ve
91  the importance of R. prolixus as vectors of Chagas disease and model organisms in insect physiology,
92                      Millions afflicted with Chagas disease and other disorders of aberrant glycosyla
93 tozoan parasites are the causative agents of Chagas disease and sleeping sickness, two neglected trop
94  associated with activation of DN T cells in Chagas disease and that CD1d blocking leads to downregul
95 ypanosoma cruzi is the causative pathogen of Chagas disease and the main culprit for cardiac-related
96 e indeterminate or cardiac clinical forms of Chagas disease and whether IL-17 expression can be corre
97 e associated with microthrombus formation in Chagas' disease and a known activator of iPLA2, increase
98  Trypanosoma brucei are parasites that cause Chagas' disease and African sleeping sickness, respectiv
99 harmacological interventions in the areas of Chagas' disease and experimental cancer.
100 sue relationship between T. cruzi infection, Chagas disease, and host glucose homeostasis.
101 parasites in murine models of leishmaniasis, Chagas disease, and human African trypanosomiasis.
102  Trypanosoma cruzi is the causative agent of Chagas disease, and infects 5-8 million people in Latin
103 ich in humans cause African trypanosomiasis, Chagas disease, and leishmaniasis, respectively.
104 kungunya, zika, yellow fever, leishmaniasis, chagas disease, and malaria, with highest incidences in
105 a cruzi ( T. cruzi ), the causative agent of Chagas disease, and the results of structure-activity in
106 al diseases (11 with schistosomiasis, 5 with Chagas' disease, and 10 with cutaneous leishmaniasis), a
107 t in vivo behavior during the acute phase of Chagas disease; and (iii) neither nonspecific toxicity n
108 60, 95% CI: 0.36-0.99) and family history of Chagas disease (aOR: 0.58, 95% CI: 0.34-0.99).
109                            Leishmaniasis and Chagas disease are endemic in many countries, and re-eme
110 peutic strategies for the treatment of acute Chagas disease are feasible and that this approach may w
111  goal of delivering a new drug candidate for Chagas disease are reported.
112              Current therapeutic options for Chagas' disease are limited to benznidazole and nifurtim
113 intracellular protozoan parasite that causes Chagas disease as a zoonotic pathogen.
114  Trypanosoma cruzi, the etiological agent of Chagas disease, as well as other trypanosomatids relevan
115                                              Chagas disease-associated cardiomyopathy is clinically s
116  evidenced by recent microepidemics of acute Chagas disease attributed to the consumption of parasite
117 tential new drug target for the treatment of Chagas disease but has not been well studied.
118 on, AhR influences the development of murine Chagas disease by modulating ROS production and regulati
119             Pregnant women were screened for Chagas disease by rapid test and received confirmatory s
120 emic hypertension (SH), rheumatic fever, and Chagas' disease (C'D) are higher in LA.
121 e to another, and present case estimates for Chagas disease came from various sources, including WHO
122 Chagas disease occur annually due to chronic Chagas disease cardiomyopathy (CCC), an inflammatory car
123                                      Chronic Chagas disease cardiomyopathy, caused by Trypanosoma cru
124 opes, and applied it to develop an assay for Chagas disease caused by the protozoan parasite Trypanos
125                                              Chagas disease caused by Trypanosoma cruzi is a paradigm
126                                              Chagas disease, caused by infection with the protozoan p
127                                              Chagas disease, caused by the eukaryotic (protozoan) par
128                                              Chagas disease, caused by the intracellular protozoan pa
129                                              Chagas disease, caused by the parasite Trypanosoma cruzi
130                                              Chagas disease, caused by the parasite Trypanosoma cruzi
131                                              Chagas disease, caused by the protozoan parasite Trypano
132                                              Chagas disease, caused by the protozoan parasite Trypano
133                                              Chagas disease, caused by the protozoan Trypanosoma cruz
134                                              Chagas disease, caused by Trypanosoma cruzi parasite, wa
135                                              Chagas disease, caused by Trypanosoma cruzi, is a major
136                                              Chagas disease, caused by Trypanosoma cruzi, is an impor
137                                              Chagas' disease, caused by the hemoflagellate protozoan
138  Cardiomyopathy is a serious complication of Chagas' disease, caused by the protozoan parasite Trypan
139                                              Chagas' disease, caused by the protozoan parasite Trypan
140                                              Chagas disease causes a severe inflammatory dilated chro
141  IC50 at 11.9 and 17.2 muM against neglected Chagas' disease causing Trypanosoma cruzi, respectively.
142  age with benznidazole to prevent congenital Chagas disease (CCD), as well as the usefulness of polym
143                                              Chagas disease (CD) affects over 300 000 people in the U
144 of only 2 medications available for treating Chagas disease (CD) and currently the only drug availabl
145  we evaluated the congenital transmission of Chagas disease (CD) in a nonendemic area.
146                                              Chagas disease (CD) in the United States is severely und
147 rs for Disease Control and Prevention (CDC), Chagas disease (CD) may affect 1.31% of Latin American i
148    Trypanosoma cruzi, the causative agent of Chagas disease (CD), contains exclusively Fe-dependent s
149 linical outcomes of the disease it provokes: Chagas disease (CD).
150 e findings suggest that during the course of Chagas disease, CD8(+) T cells undergo a gradual loss of
151 sialidase (TcTS) is a key target protein for Chagas disease chemotherapy.
152 tial to fulfill the urgent need for improved Chagas disease chemotherapy.
153 riate for further development toward an anti-Chagas disease clinical candidate.
154 ecies profile is altered in individuals with Chagas disease compared with healthy controls.
155    Trypanosoma cruzi, the causative agent of Chagas disease, contains exclusively iron-dependent supe
156                                           As Chagas disease continues to expand beyond tropical and s
157 icular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) ha
158 in toxicity of benznidazole in patients with Chagas disease, determine the serum cytokine profile, an
159 se and conclude with a view of the future of Chagas disease diagnosis, pathogenesis, therapy, and pre
160 s both sensitive and specific for congenital Chagas disease diagnosis.
161              Trypanosoma cruzi, the agent of Chagas disease, does not seem to control gene expression
162 inical significance, patients diagnosed with Chagas disease, either asymptomatic or with cardiac clin
163    Trypanosoma cruzi, the causative agent of Chagas disease, encodes for an alpha-carbonic anhydrase
164 etiologic agent of American trypanosomiasis (Chagas disease), exhibiting IC(50) values in the nanomol
165  in the pathogenesis of experimental chronic Chagas disease, favoring inflammation and fibrogenesis.
166 c_5171 could be used as a novel biomarker of Chagas disease for diagnosis and to assess treatment eff
167 l and regional health and economic burden of Chagas disease from the societal perspective.
168          In vivo tests on the acute phase of Chagas disease gave parasitemia inhibition values twice
169                                         Each Chagas disease group displayed distinct gene expression
170                         Oral transmission of Chagas disease has emerged in unpredictable situations i
171 n the USA (Lyme disease $2.5 billion), where Chagas disease has not been traditionally endemic, sugge
172 costs emanate from the USA and Canada, where Chagas disease has not been traditionally endemic.
173 The role of microRNAs in the pathogenesis of Chagas disease has not been well described.
174 ffective therapy against the chronic form of Chagas disease has yet to be discovered and developed.
175 by Trypanosoma cruzi, the causative agent of Chagas disease, has recently been described, with differ
176 cardiomyopathy, the main clinical problem in Chagas' disease, has been extensively studied but is sti
177                        Preclinical models of Chagas disease have demonstrated that antigen-specific C
178 of Trypanosoma cruzi, the etiologic agent of Chagas disease, have been highly inefficient, and no end
179        Older maternal age, family history of Chagas disease, home conditions, lower education level,
180 ected Trypanosoma cruzi, the causal agent of Chagas disease, implying the existence of evasion or tol
181  substantially ameliorates symptoms of acute Chagas disease in a mouse model with no apparent toxicit
182 nous RvD1 could modulate the pathogenesis of Chagas disease in a murine model.
183           We found a 13% point prevalence of Chagas disease in a sample of New York City immigrants w
184 pecies as a means to alleviate the burden of Chagas disease in affected regions.
185 ritic cell-based immunotherapeutic for acute Chagas disease in an attempt to delay or prevent the car
186                INTERPRETATION: Screening for Chagas disease in asymptomatic Latin American adults liv
187  infection, a protozoan parasite that causes Chagas disease in humans.
188 ccounts for an estimated 22% of new cases of Chagas disease in Latin America.
189 s as means of identifying new drugs to treat Chagas disease in the acute phase with greater activity,
190 , there are approximately 8 million cases of Chagas disease in the southern cone of South America alo
191 r, 300 000 individuals are estimated to have Chagas disease in the United States.
192 ence base to improve laboratory diagnosis of Chagas disease in the United States.
193 the blood of various tetrapods and vector of Chagas' disease in humans, carries in its genome four di
194  several vertebrate hosts is responsible for Chagas' disease in Latin America.
195 zi, the protozoan parasite that causes human Chagas' disease, induces a type I interferon (IFN) (IFN-
196              Trypanosoma cruzi, the agent of Chagas' disease, infects a variety of mammalian cells in
197                                              Chagas disease is a chronic infection caused by Trypanos
198                                              Chagas disease is a chronic infection in humans caused b
199                                              Chagas disease is a deadly infection caused by the proto
200 revent the deadly cardiac pathology in human Chagas disease is a desirable and currently unattained g
201                                              Chagas disease is a major public health issue, affecting
202                                              Chagas disease is a neglected tropical disease caused by
203                                              Chagas disease is a neglected tropical disease with 6-7
204                  American Trypanosomiasis or Chagas disease is a prevalent, neglected and serious deb
205    Identifying novel therapeutic targets for Chagas disease is a scientific priority.
206                                              Chagas disease is a well-known cause of cardiomyopathy i
207                                              Chagas disease is amongst the ten most important neglect
208                                              Chagas disease is an important disease affecting million
209                                              Chagas disease is caused by the intracellular protozoan
210                                              Chagas disease is caused by the parasite Trypanosoma cru
211                                              Chagas disease is caused by the protozoan parasite Trypa
212                                              Chagas disease is caused by the protozoan parasite Trypa
213                                              Chagas disease is caused by the protozoan parasite Trypa
214                                              Chagas disease is caused by the protozoan Trypanosoma cr
215                                              Chagas disease is characterised by an acute phase, which
216                                              Chagas disease is considered the most important parasiti
217                         Oral transmission of Chagas disease is considered when >1 acute case of febri
218                                              Chagas disease is currently prevalent in European countr
219 nd mortality in areas of Latin America where Chagas disease is endemic and among infected individuals
220                                              Chagas disease is endemic in Latin America and an emergi
221   In Latin America, cardiomyopathy caused by Chagas disease is endemic.
222              The pathological progression of Chagas disease is influenced by the infiltration and tra
223                    The current treatment for Chagas disease is not satisfactory, and there is a need
224                                              Chagas disease is now an active disease in the urban cen
225 oximately 8 million people in Latin America, Chagas disease is now becoming a serious global health p
226                                              Chagas disease is one of the main public health issues i
227                                              Chagas disease is one of the major neglected diseases of
228                       The economic burden of Chagas disease is similar to or exceeds those of other p
229                                              Chagas' disease is a zoonosis prevalent in Latin America
230                                              Chagas' disease is an important cause of cardiomyopathy
231  Trypanosoma cruzi, the etiological agent of Chagas disease, is a protozoan parasite with a complex l
232 infection, which is the etiological agent of Chagas disease, is associated with intense inflammation
233 fection, schistosomiasis, leishmaniasis, and Chagas disease, is being led by nonprofit product develo
234 olvement of MBL/MASP2-associated pathways in Chagas' disease, it is currently unknown whether MBL pla
235      Trypanosoma cruzi, the causing agent of Chagas disease, leads to an activation of the immune sys
236 s against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmanias
237                                              Chagas disease, leishmaniasis and sleeping sickness affe
238 ding malaria, human African trypanosomiasis, Chagas disease, leishmaniasis, filariasis, and schistoso
239 ic Trypanosoma cruzi infection, the cause of Chagas disease, life-threatening inflammatory diseases d
240  Whether asymptomatic individuals at risk of Chagas disease living in Europe should be screened and t
241 against cruzain, a thiol protease target for Chagas disease, looking for reversible, competitive inhi
242 with at least three different techniques for Chagas disease, maintained at controlled low temperature
243 cardiac, digestive and asymptomatic) chronic Chagas disease manifestations.
244  number of infants diagnosed with congenital Chagas disease, many infants remain undiagnosed.
245 pecific diagnostic techniques for congenital Chagas disease may help improve regional initiatives to
246 gest that galectin-3 is strongly involved in Chagas disease, not only in the immune response against
247   Approximately 12000 deaths attributable to Chagas disease occur annually due to chronic Chagas dise
248 OS] in the Treatment of Asymptomatic Chronic Chagas Disease [P05267] [STOP CHAGAS]: NCT01377480).
249  The mechanisms underlying resistance of the Chagas disease parasite, Trypanosoma cruzi, to current t
250                                          The Chagas' disease parasite Trypanosoma cruzi commonly infe
251                                          The Chagas' disease parasite Trypanosoma cruzi elicits a pot
252 verall, this work provides new insights into Chagas disease pathogenesis and presents an analytical c
253  >100 years ago, much has been learned about Chagas disease pathogenesis; however, the outcome of T.
254  Prospective observational study where adult Chagas disease patients accepting to receive benznidazol
255              Only a minority of samples from Chagas disease patients possessed antibodies against rLb
256                 Similarly, symptomatic acute Chagas' disease patients displayed increased serum conce
257 nstrated to induce CD8(+) T cell response in Chagas' disease patients, or bind HLA-A*02:01, but are,
258 gainst PBMC samples from a cohort of chronic Chagas' disease patients, using IFN-gamma secretion as a
259        The US-based Center of Excellence for Chagas Disease performed an observational study on the s
260 at Trypanosoma cruzi, the etiologic agent of Chagas disease, possesses two unique paralogues of the m
261                     Even with a reduction in Chagas disease prevalence to 0.05% and with large variat
262 ytotoxicity could play a role in determining Chagas disease progression.
263              Trypanosoma cruzi, the agent of Chagas' disease, promotes neuron survival through recept
264 ted therapeutic options to prevent and treat Chagas disease put 8 million people infected with T. cru
265  role of autoimmunity in the pathogenesis of Chagas disease remain unanswered, the development of aut
266 ver, occurrence of primary RV dysfunction in Chagas disease remains controversial.
267 panosomes are causative agents of Nagana and Chagas disease respectively, and speciated about 300 mil
268 hose with the indeterminate clinical form of Chagas disease, respectively.
269 investigated include malaria, leishmaniasis, Chagas' disease, roundworm, whipworm, pinworm, Chinese l
270                                   In chronic Chagas disease, RV systolic dysfunction is more commonly
271 rformed an economic evaluation of systematic Chagas disease screening of the Latin American populatio
272 ole treatment, of patients with asymptomatic Chagas disease showed a significant reduction in antigen
273 es responsible for such human pathologies as Chagas disease, sleeping sickness, and leishmaniasis.
274  since the 1990s, but symptomatic congenital Chagas disease still represents a significant, albeit ch
275 iomyocytes, as well as in the mouse model of Chagas disease, supporting the involvement of TcAPx-CcP
276 eir partnership in the immunopathogenesis of Chagas disease, the chronic infection caused by the intr
277  Trypanosoma cruzi, the parasite that causes Chagas disease, the elongated, flagellated trypomastigot
278 te the possibility of using RDTs to diagnose Chagas disease, thereby decreasing the time to treatment
279                         In Venezuela, active Chagas disease transmission has been reported, with sero
280 te than benznidazole, the drug of choice for Chagas disease treatment, the ant alkaloids presented a
281 a cruzi parasite is the etiological agent of Chagas disease, treatment is still plagued by limited ef
282 date tipifarnib kills the causative agent of Chagas disease, Trypanosoma cruzi, by blocking ergostero
283 of genomic DNA from the parasite that causes Chagas disease, Trypanosoma cruzi, directly in whole, un
284 e: Trypanosoma cruzi, the causative agent of Chagas disease; Trypanosoma brucei, the causative agent
285  study RV systolic function in patients with Chagas disease using cardiac magnetic resonance.
286 o cross-sectional data of infestation by the Chagas disease vector Triatoma infestans in the city of
287 ling the position of major clades (e.g., the Chagas disease vectors Triatominae).
288 against both the acute and chronic phases of Chagas disease was considered.
289                                              Chagas disease was diagnosed in 25 (19%) patients.
290 with Rhodnius prolixus, the insect vector of Chagas disease, we show that an ovary dual oxidase (Duox
291       To discover new possible therapies for Chagas' disease, we evaluated against all Trypanosoma cr
292 ne bug Rhodnius prolixus is a main vector of Chagas disease, which affects several million people, mo
293                Trypanosoma cruzi (TC) causes Chagas disease, which in its chronic stage remains incur
294                                              Chagas disease, which was once thought to be confined to
295  study included 158 individuals with chronic Chagas disease who underwent cardiac magnetic resonance.
296 an heart samples obtained from subjects with Chagas disease who underwent heart transplantation showe
297 cellular experiments, cures the experimental Chagas disease with 100% efficacy, and suppresses viscer
298 HF) with reduced ejection fraction caused by Chagas' disease, with other etiologies, in the era of mo
299 ical aspects of the disease, such as chronic Chagas disease without detectable cardiac pathology, as
300 soma cruzi leads to the development of human Chagas' disease, yet the functional contributions of the

 
Page Top